BARD1 and breast cancer: Due to the pronounced association with early-onset BC (AAD < 40 years: OR = 12.04; AAD < 50 years: OR = 7.43), we suggest that BARD1 should be included in multigene panels for BC risk assessment and, due to the comparatively young AAD of BC observed, intensified BC surveillance programs should be offered to women carrying pathogenic variants in BARD1.